[
  {
    "question": {
      "question_id": "cs03_q05_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "negative",
      "prompt": "Is there evidence of nephrotoxicity or renal dysfunction in enrolled subjects?",
      "ground_truth": {
        "canonical_answer": "No. Renal panels (creatinine, BUN, eGFR) remain within normal limits throughout the trial. The emerging safety signal is hepatic, not renal.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_004",
          "clinical_signal_03_ep_011"
        ],
        "key_facts": [
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q05_negative",
      "answer_text": "The retrieved documents do not provide evidence of nephrotoxicity or renal dysfunction in enrolled subjects. The search results consist of daily operations summaries that report enrollment numbers, site-specific data, and concomitant medication use (e.g., statins), but none mention renal adverse events, laboratory markers of kidney function (such as serum creatinine or eGFR), or nephrotoxicity signals [clinical_signal_03_ep_008][clinical_signal_03_ep_006][clinical_signal_03_ep_004][clinical_signal_03_ep_013][clinical_signal_03_ep_007][clinical_signal_03_ep_005][clinical_signal_03_ep_011]. Therefore, based on the available information, there is no indication of renal dysfunction or nephrotoxicity in the enrolled subjects.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_46779ba766954e8ea61ce95b",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 749
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_46779ba766954e8ea61ce95b",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_ec09c2245aeb4edeb51861a5",
              "name": "memory_search",
              "arguments": {
                "query": "nephrotoxicity renal dysfunction enrolled subjects",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1052
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_ec09c2245aeb4edeb51861a5",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_008\", \"text\": \"## 2024-04-22 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 180\\n- Active: 177\\n- Screen Failures Cumulative: 13\\n- Withdrawals Cumulative: 3\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 13\\n- Site 02 Active: 13\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 16\\n- Site 03 Active: 16\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.032018442622950824, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_006\", \"text\": \"## 2024-04-08 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 140\\n- Active: 137\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 3\\n\\n#### Sites\\n- Site 01 Enrolled: 14\\n- Site 01 Active: 14\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 10\\n- Site 02 Active: 10\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 18\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 9\\n- Site 04 Active: 9\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 11\\n- Site 05\", \"score\": 0.03149801587301587, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 100\\n- Active: 98\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 10\\n  - Active: 10\\n  - Statin Concomitant: 2\\n- Site 02\\n  - Enrolled: 7\\n  - Active: 7\\n  - Statin Concomitant: 1\\n- Site 03\\n  - Enrolled: 9\\n  - Active: 9\\n  - Statin Concomitant: 2\\n- Site 04\\n  - Enrolled: 6\\n  - Active: 6\\n  - Statin Concomitant: 1\\n- Site 05\\n  - Enrolled: 8\\n  - Active: 8\\n  - Statin Concomitant: 2\\n- S\", \"score\": 0.03128054740957967, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_013\", \"text\": \"## 2024-05-27 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 195\\n- Active: 191\\n- Screen Failures Cumulative: 29\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.030886196246139225, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_007\", \"text\": \"## 2024-04-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 160\\n- Active: 156\\n- Screen Failures Cumulative: 15\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01 Enrolled: 16\\n- Site 01 Active: 16\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 12\\n- Site 02 Active: 12\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 15\\n- Site 03 Active: 15\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 10\\n- Site 04 Active: 10\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 13\\n- Site \", \"score\": 0.030834914611005692, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 120\\n- Active: 118\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 12\\n- Site 01 Active: 12\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 9\\n- Site 02 Active: 9\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 11\\n- Site 03 Active: 11\\n- Site 03 Statin Concomitant: 3\\n- Site 04 Enrolled: 8\\n- Site 04 Active: 8\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 10\\n- Site 05 A\", \"score\": 0.030798389007344232, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.029877369007803793, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_b45542a2d6014642a17123b4",
              "name": "memory_search",
              "arguments": {
                "query": "renal function nephrotoxicity adverse events",
                "limit": 7
              }
            }
          ],
          "tokens_used": 3167
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_b45542a2d6014642a17123b4",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The retrieved documents do not provide evidence of nephrotoxicity or renal dysfunction in enrolled subjects. The search results consist of daily operations summaries that report enrollment numbers, site-specific data, and concomitant medication use (e.g., statins), but none mention renal adverse events, laboratory markers of kidney function (such as serum creatinine or eGFR), or nephrotoxicity signals [clinical_signal_03_ep_008][clinical_signal_03_ep_006][clinical_signal_03_ep_004][clinical_signal_03_ep_013][clinical_signal_03_ep_007][clinical_signal_03_ep_005][clinical_signal_03_ep_011]. Therefore, based on the available information, there is no indication of renal dysfunction or nephrotoxicity in the enrolled subjects.",
          "tokens_used": 3377
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8345,
      "wall_time_ms": 12059.710631961934,
      "budget_violations": [
        "Cumulative result token limit exceeded: 2693 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_008",
        "clinical_signal_03_ep_006",
        "clinical_signal_03_ep_004",
        "clinical_signal_03_ep_013",
        "clinical_signal_03_ep_007",
        "clinical_signal_03_ep_005",
        "clinical_signal_03_ep_011"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_008",
      "clinical_signal_03_ep_006",
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_013",
      "clinical_signal_03_ep_007",
      "clinical_signal_03_ep_005",
      "clinical_signal_03_ep_011"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_008",
      "clinical_signal_03_ep_006",
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_013",
      "clinical_signal_03_ep_007",
      "clinical_signal_03_ep_005",
      "clinical_signal_03_ep_011"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q18_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "temporal",
      "prompt": "When did the first hepatic enzyme elevations appear relative to drug exposure initiation?",
      "ground_truth": {
        "canonical_answer": "Hepatic enzyme elevations first appeared during the early signal phase, approximately weeks 9-10 of the trial, several weeks after subjects began receiving LNS-4821 with concomitant statin therapy.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q18_temporal",
      "answer_text": "The provided search results do not contain specific information about the timing of the first hepatic enzyme elevations relative to drug exposure initiation. The documents retrieved are daily operations summaries focusing on enrollment, site activity, and concomitant medication use, but they do not report clinical laboratory findings or adverse events such as hepatic enzyme elevations [clinical_signal_03_ep_011, clinical_signal_03_ep_015, clinical_signal_03_ep_001, clinical_signal_03_ep_009, clinical_signal_03_ep_013, clinical_signal_03_ep_002, clinical_signal_03_ep_010]. Therefore, based on the available data, the timing of the first hepatic enzyme elevations cannot be determined.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_9b5112d4ba0b4287860896a2",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 749
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_9b5112d4ba0b4287860896a2",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_a60bea9984d54e48b8f8d6dc",
              "name": "memory_search",
              "arguments": {
                "query": "first hepatic enzyme elevations timing after drug exposure initiation",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1053
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_a60bea9984d54e48b8f8d6dc",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.03149801587301587, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_015\", \"text\": \"## 2024-06-10 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 215\\n- Active: 208\\n- Screen Failures Cumulative: 33\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 18\\n- Site \", \"score\": 0.031054405392392875, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_001\", \"text\": \"## 2024-03-04 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 40\\n- Active: 40\\n- Screen Failures Cumulative: 2\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01: \\n  - Enrolled: 4\\n  - Active: 4\\n  - Statin Concomitant: 1\\n- Site 02: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 03: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 04: \\n  - Enrolled: 2\\n  - Active: 2\\n  - Statin Concomitant: 0\\n- Site 05: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant:\", \"score\": 0.030679156908665108, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 185\\n- Active: 180\\n- Screen Failures Cumulative: 22\\n- Withdrawals Cumulative: 5\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.030679156908665108, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_013\", \"text\": \"## 2024-05-27 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 195\\n- Active: 191\\n- Screen Failures Cumulative: 29\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.030621785881252923, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 60\\n- Active: 60\\n- Screen Failures Cumulative: 4\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 6\\n- Site 01 Active: 6\\n- Site 01 Statin Concomitant: 1\\n- Site 02 Enrolled: 4\\n- Site 02 Active: 4\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 5\\n- Site 03 Active: 5\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 4\\n- Site 04 Active: 4\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 5\\n- Site 05 Active: 5\", \"score\": 0.030309988518943745, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_010\", \"text\": \"## 2024-05-06 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 184\\n- Active: 182\\n- Screen Failures Cumulative: 20\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.029957522915269395, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_3372e343677b471799555283",
              "name": "memory_search",
              "arguments": {
                "query": "hepatic enzyme elevations onset time after drug initiation",
                "limit": 7
              }
            }
          ],
          "tokens_used": 3168
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_3372e343677b471799555283",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The provided search results do not contain specific information about the timing of the first hepatic enzyme elevations relative to drug exposure initiation. The documents retrieved are daily operations summaries focusing on enrollment, site activity, and concomitant medication use, but they do not report clinical laboratory findings or adverse events such as hepatic enzyme elevations [clinical_signal_03_ep_011, clinical_signal_03_ep_015, clinical_signal_03_ep_001, clinical_signal_03_ep_009, clinical_signal_03_ep_013, clinical_signal_03_ep_002, clinical_signal_03_ep_010]. Therefore, based on the available data, the timing of the first hepatic enzyme elevations cannot be determined.",
          "tokens_used": 3359
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8329,
      "wall_time_ms": 10885.86118700914,
      "budget_violations": [
        "Cumulative result token limit exceeded: 2697 > 2048"
      ],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q19_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "distractor_resistance",
      "prompt": "Are novel urinary biomarkers (KIM-1, NGAL) showing any abnormalities in trial subjects?",
      "ground_truth": {
        "canonical_answer": "No. Renal biomarkers remain within normal limits. The emerging safety signal is hepatic (ALT/AST elevation), not renal.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_004",
          "clinical_signal_03_ep_011"
        ],
        "key_facts": [
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q19_distractor",
      "answer_text": "The search results do not contain any information about the novel urinary biomarkers KIM-1 or NGAL, nor do they mention abnormalities related to these biomarkers in trial subjects. The provided documents focus on standard lab panel metrics such as ALT, AST, creatinine, and bilirubin, but do not include data on urinary biomarkers [clinical_signal_03_ep_014][clinical_signal_03_ep_004][clinical_signal_03_ep_005]. Therefore, based on the available information, there is no evidence of abnormalities in KIM-1 or NGAL levels in trial subjects.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_616d12e39eff483783eab130",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 754
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_616d12e39eff483783eab130",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_2c1408d43cbc4cf9bbc8c6c9",
              "name": "memory_search",
              "arguments": {
                "query": "KIM-1 NGAL urinary biomarkers abnormalities trial subjects",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1059
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_2c1408d43cbc4cf9bbc8c6c9",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_014\", \"text\": \"## 2024-06-03 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 53\\n- ALT (U/L) Mean: 57.6\\n- ALT (U/L) Median: 56.0\\n- AST (U/L) Mean: 45.7\\n- AST (U/L) Median: 45.7\\n- Bilirubin (mg/dL) Mean: 0.86\\n- Bilirubin (mg/dL) Median: 0.83\\n- ALP (U/L) Mean: 65.4\\n- ALP (U/L) Median: 57.0\\n- Creatinine (mg/dL) Mean: 0.89\\n- Creatinine (mg/dL) Median: 0.85\\n- BUN (mg/dL) Mean: 14.7\\n- BUN (mg/dL) Median: 13.1\\n- WBC (K) Mean: 6.2\\n- WBC (K) Median: 7.0\\n- Platelets (K) Mean: 223\\n- Platelets (K) Median:\", \"score\": 0.03278688524590164, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 52\\n- ALT (U/L) Mean: 24.6\\n- ALT (U/L) Median: 23.8\\n- AST (U/L) Mean: 23.6\\n- AST (U/L) Median: 23.2\\n- Bilirubin (mg/dL) Mean: 0.86\\n- Bilirubin (mg/dL) Median: 0.84\\n- ALP (U/L) Mean: 73.7\\n- ALP (U/L) Median: 63.8\\n- Creatinine (mg/dL) Mean: 1.06\\n- Creatinine (mg/dL) Median: 0.92\\n- BUN (mg/dL) Mean: 13.3\\n- BUN (mg/dL) Median: 13.0\\n- WBC (K) Mean: 8.2\\n- WBC (K) Median: 5.5\\n- Platelets (K) Mean: 235\\n- Platelets (K) Median:\", \"score\": 0.03252247488101534, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 56\\n- ALT (U/L) Mean: 26.3\\n- ALT (U/L) Median: 25.5\\n- AST (U/L) Mean: 22.6\\n- AST (U/L) Median: 22.4\\n- Bilirubin (mg/dL) Mean: 0.67\\n- Bilirubin (mg/dL) Median: 0.65\\n- ALP (U/L) Mean: 68.6\\n- ALP (U/L) Median: 79.7\\n- Creatinine (mg/dL) Mean: 1.02\\n- Creatinine (mg/dL) Median: 0.97\\n- BUN (mg/dL) Mean: 17.6\\n- BUN (mg/dL) Median: 11.1\\n- WBC (K) Mean: 6.2\\n- WBC (K) Median: 6.1\\n- Platelets (K) Mean: 258\\n- Platelets (K) Median:\", \"score\": 0.032266458495966696, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup N: 55\\n- Statin Subgroup ALT (U/L) Mean: 26.0\\n- Statin Subgroup ALT (U/L) Median: 24.3\\n- Statin Subgroup AST (U/L) Mean: 27.9\\n- Statin Subgroup AST (U/L) Median: 25.9\\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.59\\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.56\\n- Statin Subgroup ALP (U/L) Mean: 79.3\\n- Statin Subgroup ALP (U/L) Median: 57.2\\n- Statin Subgroup Creatinine (mg/dL) Mean: 1.04\\n- Statin Subgroup Creatinine (mg/dL) M\", \"score\": 0.032018442622950824, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup N: 53\\n- Statin Subgroup ALT (U/L) Mean: 26.8\\n- Statin Subgroup ALT (U/L) Median: 26.3\\n- Statin Subgroup AST (U/L) Mean: 22.1\\n- Statin Subgroup AST (U/L) Median: 20.8\\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.73\\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.72\\n- Statin Subgroup ALP (U/L) Mean: 71.0\\n- Statin Subgroup ALP (U/L) Median: 75.0\\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.85\\n- Statin Subgroup Creatinine (mg/dL) M\", \"score\": 0.03177805800756621, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_001\", \"text\": \"## 2024-03-04 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup:\\n  - N: 53\\n  - ALT (U/L) Mean: 25.5\\n  - ALT (U/L) Median: 22.7\\n  - AST (U/L) Mean: 26.4\\n  - AST (U/L) Median: 24.4\\n  - Bilirubin (mg/dL) Mean: 0.78\\n  - Bilirubin (mg/dL) Median: 0.74\\n  - ALP (U/L) Mean: 84.9\\n  - ALP (U/L) Median: 76.7\\n  - Creatinine (mg/dL) Mean: 1.06\\n  - Creatinine (mg/dL) Median: 0.95\\n  - BUN (mg/dL) Mean: 16.9\\n  - BUN (mg/dL) Median: 15.1\\n  - WBC (K) Mean: 5.9\\n  - WBC (K) Median: 7.6\\n  - Platelets (K) Mea\", \"score\": 0.031544957774465976, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_015\", \"text\": \"## 2024-06-10 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 54\\n- ALT (U/L) Mean: 62.2\\n- ALT (U/L) Median: 61.3\\n- AST (U/L) Mean: 51.0\\n- AST (U/L) Median: 50.3\\n- Bilirubin (mg/dL) Mean: 0.89\\n- Bilirubin (mg/dL) Median: 0.86\\n- ALP (U/L) Mean: 58.6\\n- ALP (U/L) Median: 78.4\\n- Creatinine (mg/dL) Mean: 0.97\\n- Creatinine (mg/dL) Median: 0.8\\n- BUN (mg/dL) Mean: 14.8\\n- BUN (mg/dL) Median: 16.3\\n- WBC (K) Mean: 6.4\\n- WBC (K) Median: 7.9\\n- Platelets (K) Mean: 241\\n- Platelets (K) Median: \", \"score\": 0.03131881575727918, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The search results do not contain any information about the novel urinary biomarkers KIM-1 or NGAL, nor do they mention abnormalities related to these biomarkers in trial subjects. The provided documents focus on standard lab panel metrics such as ALT, AST, creatinine, and bilirubin, but do not include data on urinary biomarkers [clinical_signal_03_ep_014][clinical_signal_03_ep_004][clinical_signal_03_ep_005]. Therefore, based on the available information, there is no evidence of abnormalities in KIM-1 or NGAL levels in trial subjects.",
          "tokens_used": 3457
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 5270,
      "wall_time_ms": 6191.220119013451,
      "budget_violations": [],
      "refs_cited": [
        "clinical_signal_03_ep_014",
        "clinical_signal_03_ep_004",
        "clinical_signal_03_ep_005"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_014",
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_005"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_014",
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_005"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q24_evidence",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "evidence_sufficiency",
      "prompt": "Is there sufficient evidence at this point to convene a DSMB safety review?",
      "ground_truth": {
        "canonical_answer": "Borderline. The ALT trend in the statin subgroup is concerning but individual values are still below protocol action thresholds. A few more weeks of data showing continued escalation would strengthen the case for DSMB review.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q24_evidence",
      "answer_text": "Based on the available information retrieved from the memory system, there is insufficient evidence to determine whether a DSMB safety review should be convened. The search results primarily contain daily operations summaries, enrollment data, and protocol deviations, but do not include specific DSMB charter criteria, safety thresholds, or serious adverse events that would trigger a safety review [clinical_signal_03_ep_008, clinical_signal_03_ep_012, clinical_signal_03_ep_004]. \n\nWhile there are several protocol deviations noted (such as dose modifications without PI approval and temperature excursions), these are categorized as minor to moderate in severity and do not, on their own, indicate a pattern of safety concerns that would typically warrant a DSMB review [clinical_signal_03_ep_009, clinical_signal_03_ep_013, clinical_signal_03_ep_002]. \n\nWithout access to the DSMB charter, predefined safety stopping rules, or data on serious adverse events, it is not possible to conclude that sufficient evidence exists to convene a DSMB safety review at this time.",
      "turns": [
        {
          "role": "assistant",
          "content": "I need to determine if there is sufficient evidence to convene a DSMB safety review. Let me first check the memory system capabilities to understand what information is available.",
          "tool_calls": [
            {
              "id": "call_24b912a1a3f6435f82d273ac",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 782
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_24b912a1a3f6435f82d273ac",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "Now I'll search for information related to DSMB (Data and Safety Monitoring Board) safety reviews, focusing on criteria or evidence that would trigger such a review. I'll use a keyword search to find relevant documents.",
          "tool_calls": [
            {
              "id": "call_e4e7c37cdc3345dd95602c9a",
              "name": "memory_search",
              "arguments": {
                "query": "DSMB safety review criteria",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1123
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_e4e7c37cdc3345dd95602c9a",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_008\", \"text\": \"## 2024-04-22 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 180\\n- Active: 177\\n- Screen Failures Cumulative: 13\\n- Withdrawals Cumulative: 3\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 13\\n- Site 02 Active: 13\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 16\\n- Site 03 Active: 16\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.03225806451612903, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_012\", \"text\": \"## 2024-05-20 Daily Operations Summary\\n### Protocol Deviations\\n- PD ID: PD-026\\n  - Description: Dose modification without documented PI approval\\n  - Severity: moderate\\n  - Site: site_07\", \"score\": 0.03177805800756621, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 100\\n- Active: 98\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 10\\n  - Active: 10\\n  - Statin Concomitant: 2\\n- Site 02\\n  - Enrolled: 7\\n  - Active: 7\\n  - Statin Concomitant: 1\\n- Site 03\\n  - Enrolled: 9\\n  - Active: 9\\n  - Statin Concomitant: 2\\n- Site 04\\n  - Enrolled: 6\\n  - Active: 6\\n  - Statin Concomitant: 1\\n- Site 05\\n  - Enrolled: 8\\n  - Active: 8\\n  - Statin Concomitant: 2\\n- S\", \"score\": 0.031544957774465976, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n### Protocol Deviations\\n- PD ID: PD-021, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_08\\n- PD ID: PD-022, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_10\\n- PD ID: PD-023, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_05\", \"score\": 0.03125763125763126, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_013\", \"text\": \"## 2024-05-27 Daily Operations Summary\\n### Protocol Deviations\\n- PD ID: PD-027, Description: Missed visit window (3 days late), Severity: minor, Site: site_01\\n- PD ID: PD-028, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_08\", \"score\": 0.031009615384615385, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n### Protocol Deviations\\n- PD ID: PD-004, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_02\\n- PD ID: PD-005, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_05\\n- PD ID: PD-006, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_12\", \"score\": 0.03076923076923077, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_006\", \"text\": \"## 2024-04-08 Daily Operations Summary\\n### Protocol Deviations\\n- PD ID: PD-014, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_10\\n- PD ID: PD-015, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_12\\n- PD ID: PD-016, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_04\", \"score\": 0.030309988518943745, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I don't see any direct information about DSMB safety review criteria or specific safety signals that would trigger a review in the initial search results. Let me try a more targeted search for DSMB-related documents or safety thresholds.",
          "tool_calls": [
            {
              "id": "call_b361c443b3594e0396d5ce18",
              "name": "memory_search",
              "arguments": {
                "query": "DSMB safety thresholds",
                "limit": 7
              }
            }
          ],
          "tokens_used": 2650
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_b361c443b3594e0396d5ce18",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "Based on the available information retrieved from the memory system, there is insufficient evidence to determine whether a DSMB safety review should be convened. The search results primarily contain daily operations summaries, enrollment data, and protocol deviations, but do not include specific DSMB charter criteria, safety thresholds, or serious adverse events that would trigger a safety review [clinical_signal_03_ep_008, clinical_signal_03_ep_012, clinical_signal_03_ep_004]. \n\nWhile there are several protocol deviations noted (such as dose modifications without PI approval and temperature excursions), these are categorized as minor to moderate in severity and do not, on their own, indicate a pattern of safety concerns that would typically warrant a DSMB review [clinical_signal_03_ep_009, clinical_signal_03_ep_013, clinical_signal_03_ep_002]. \n\nWithout access to the DSMB charter, predefined safety stopping rules, or data on serious adverse events, it is not possible to conclude that sufficient evidence exists to convene a DSMB safety review at this time.",
          "tokens_used": 2905
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 7460,
      "wall_time_ms": 15058.619567891583,
      "budget_violations": [
        "Cumulative result token limit exceeded: 2176 > 2048"
      ],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  }
]